- Home
- MNPR vs SWZ Comparison
MNPR vs SWZ Comparison
Compare MNPR & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- SWZ
- Stock Information
- Founded
- MNPR 2014
- SWZ 1986
- Country
- MNPR United States
- SWZ United States
- Employees
- MNPR N/A
- SWZ N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- SWZ Finance Companies
- Sector
- MNPR Health Care
- SWZ Finance
- Exchange
- MNPR Nasdaq
- SWZ Nasdaq
- Market Cap
- MNPR 95.5M
- SWZ 109.6M
- IPO Year
- MNPR 2019
- SWZ N/A
- Fundamental
- Price
- MNPR $18.09
- SWZ $7.87
- Analyst Decision
- MNPR Strong Buy
- SWZ
- Analyst Count
- MNPR 3
- SWZ 0
- Target Price
- MNPR $27.33
- SWZ N/A
- AVG Volume (30 Days)
- MNPR 1.5M
- SWZ 14.2K
- Earning Date
- MNPR 11-08-2024
- SWZ 01-01-0001
- Dividend Yield
- MNPR N/A
- SWZ 6.59%
- EPS Growth
- MNPR N/A
- SWZ N/A
- EPS
- MNPR N/A
- SWZ N/A
- Revenue
- MNPR N/A
- SWZ N/A
- Revenue This Year
- MNPR N/A
- SWZ N/A
- Revenue Next Year
- MNPR N/A
- SWZ N/A
- P/E Ratio
- MNPR N/A
- SWZ N/A
- Revenue Growth
- MNPR N/A
- SWZ N/A
- 52 Week Low
- MNPR $1.37
- SWZ $7.12
- 52 Week High
- MNPR $38.50
- SWZ $8.57
- Technical
- Relative Strength Index (RSI)
- MNPR 60.19
- SWZ 26.23
- Support Level
- MNPR $16.26
- SWZ $7.82
- Resistance Level
- MNPR $19.70
- SWZ $8.14
- Average True Range (ATR)
- MNPR 2.15
- SWZ 0.12
- MACD
- MNPR -0.07
- SWZ -0.02
- Stochastic Oscillator
- MNPR 74.36
- SWZ 8.06
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, and retail.